亚宝药业
(600351)
| 流通市值：43.85亿 | | | 总市值：43.85亿 |
| 流通股本：7.20亿 | | | 总股本：7.20亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,121,509,818.79 | 1,443,686,437.98 | 771,213,413.14 | 2,909,765,256.74 |
| 营业收入 | 2,121,509,818.79 | 1,443,686,437.98 | 771,213,413.14 | 2,909,765,256.74 |
| 二、营业总成本 | 1,854,942,934.53 | 1,246,402,129.14 | 644,615,339.06 | 2,620,740,517.25 |
| 营业成本 | 1,023,628,071.91 | 659,977,902.29 | 336,338,751.8 | 1,226,341,851.74 |
| 税金及附加 | 26,570,623.72 | 18,402,929.58 | 10,057,933.64 | 35,285,959.29 |
| 销售费用 | 514,819,616.99 | 371,483,141.9 | 200,638,292.84 | 971,690,618.15 |
| 管理费用 | 200,458,781.73 | 127,507,085.8 | 66,748,757.12 | 265,909,082.3 |
| 研发费用 | 89,911,769.62 | 68,902,062.59 | 31,012,841.2 | 118,289,869.23 |
| 财务费用 | -445,929.44 | 129,006.98 | -181,237.54 | 3,223,136.54 |
| 其中:利息费用 | 4,660,671.71 | 3,616,649.05 | 1,834,594.18 | 12,298,232.82 |
| 其中:利息收入 | 5,310,753.39 | 3,625,373.96 | 2,059,471.68 | 9,486,872.16 |
| 加:公允价值变动收益 | 104,653.02 | 33,791.92 | -6,744.61 | -2,582,034.12 |
| 加:投资收益 | 82,208.83 | 135,319.7 | 223,745.26 | -2,763,516.28 |
| 资产处置收益 | 175,751.27 | 56,382.98 | 44.28 | 1,121,960.35 |
| 资产减值损失(新) | -6,806,022.31 | -5,988,652.34 | -235,384.3 | -93,749,254.15 |
| 信用减值损失(新) | 1,362,672.84 | -1,229,465.99 | -835,836.03 | 2,071,445.77 |
| 其他收益 | 26,887,624.07 | 21,849,900.86 | 11,194,349.24 | 33,211,691.29 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 288,373,771.98 | 212,141,585.97 | 136,938,247.92 | 226,335,032.35 |
| 加:营业外收入 | 1,158,966.09 | 1,031,924.49 | 570,042.61 | 2,954,284.62 |
| 减:营业外支出 | 5,521,404.09 | 367,397.88 | 120,924.26 | 10,308,094.32 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 284,011,333.98 | 212,806,112.58 | 137,387,366.27 | 218,981,222.65 |
| 减:所得税费用 | 55,543,479.47 | 37,614,335.23 | 27,615,361.72 | 39,067,537.42 |
| 六、净利润 | 228,467,854.51 | 175,191,777.35 | 109,772,004.55 | 179,913,685.23 |
| 持续经营净利润 | 228,467,854.51 | 175,191,777.35 | 109,772,004.55 | 179,913,685.23 |
| 归属于母公司股东的净利润 | 234,933,135.46 | 179,774,385.13 | 112,264,323.74 | 199,585,789.8 |
| 少数股东损益 | -6,465,280.95 | -4,582,607.78 | -2,492,319.19 | -19,672,104.57 |
| (一)基本每股收益 | 0.32 | 0.25 | 0.15 | 0.26 |
| (二)稀释每股收益 | - | - | 0.15 | - |
| 八、其他综合收益 | - | - | - | -4,402,698.14 |
| 归属于母公司股东的其他综合收益 | - | - | - | -4,402,698.14 |
| 九、综合收益总额 | 228,467,854.51 | 175,191,777.35 | 109,772,004.55 | 175,510,987.09 |
| 归属于母公司股东的综合收益总额 | 234,933,135.46 | 179,774,385.13 | 112,264,323.74 | 195,183,091.66 |
| 归属于少数股东的综合收益总额 | -6,465,280.95 | -4,582,607.78 | -2,492,319.19 | -19,672,104.57 |
| 公告日期 | 2024-10-25 | 2024-08-15 | 2024-04-26 | 2024-04-26 |
| 审计意见(境内) | | | | 标准无保留意见 |